Loading...

Leslie M. Thompson

Title(s)Professor, Neurobiology & Behavior
Address3214 Bio Sci lll
Zot 4545
Irvine CA 92697
Phone(949) 824-6756, 1910
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    A Vascularized Micro-Organ platform for the study of Brain-BBB-Blood interaction
    NIH R61HL154307Sep 3, 2020 - Aug 31, 2022
    Role: Co-Principal Investigator
    Molecular Mechanisms of Pathogenesis in Huntington?s disease
    NIH R35NS116872May 1, 2020 - Apr 30, 2028
    Role: Principal Investigator
    From Structure to Therapy: The TRiC Chaperonin Network in Huntington's Disease
    NIH P01NS092525Apr 1, 2016 - Aug 31, 2019
    Role: Principal Investigator
    Neuroregulatory Mechanisms of PIAS1 and Implications for Huntington's Disease
    NIH R01NS090390Jul 15, 2015 - Jun 30, 2020
    Role: Principal Investigator
    Genome editing in HD iPS cells to reduce mutant and total Huntington expression
    NIH R21NS090395Jul 15, 2015 - Jun 30, 2018
    Role: Principal Investigator
    Epigenetic pathology and therapy in Huntington's disease
    NIH R01NS089076Apr 1, 2015 - Jul 31, 2020
    Role: Co-Principal Investigator
    Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells
    NIH U54NS091046Sep 30, 2014 - Jun 30, 2021
    Role: Principal Investigator
    Neuroregulatory Mechanisms of PIAS1 and Implications for Huntington's Disease
    NIH R56NS090390Sep 30, 2014 - Feb 29, 2016
    Role: Principal Investigator
    In vivo longitudinal assessment of methylene blue for Huntington's disease
    NIH R03NS081260Jan 1, 2014 - Aug 31, 2016
    Role: Principal Investigator
    Training Program in Stem Cell Translational Medicine for Neurological Disorders
    NIH T32NS082174Jul 1, 2013 - Jun 30, 2023
    Role: Principal Investigator
    CAG Triplet Repeat Disorders
    NIH R13NS083250Apr 1, 2013 - Mar 31, 2014
    Role: Principal Investigator
    The HD iPSC Consortium: Repeat Length Dependent Phenotypes for Assay Development
    NIH U24NS078370Jul 1, 2012 - Jun 30, 2015
    Role: Principal Investigator
    The Histone Demethylase SMCX/JARED1C as a Therapeutic Target for Huntington's Dis
    NIH R21NS072793Apr 1, 2011 - Mar 31, 2013
    Role: Principal Investigator
    The Huntington's Disease iPS Consortium
    NIH RC2NS069422Sep 30, 2009 - Aug 31, 2012
    Role: Co-Principal Investigator
    Pathogenic Impact of SUMO modification in Huntington's disease
    NIH R01NS052789Jun 1, 2006 - May 31, 2012
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. PIAS1 modulates striatal transcription, DNA damage repair, and SUMOylation with relevance to Huntington's disease. Proc Natl Acad Sci U S A. 2021 Jan 26; 118(4). Morozko EL, Smith-Geater C, Monteys AM, Pradhan S, Lim RG, Langfelder P, Kachemov M, Hill A, Stocksdale JT, Cullis PR, Wu J, Ochaba J, Miramontes R, Chakraborty A, Hazra TK, Lau A, St-Cyr S, Orellana I, Kopan L, Wang KQ, Yeung S, Leavitt BR, Reidling JC, Yang XW, Steffan JS, Davidson BL, Sarkar PS, Thompson LM. PMID: 33468657.
      View in: PubMed   Mentions:    Fields:    
    2. Development and external validation of a prognostic tool for COVID-19 critical disease. PLoS One. 2020; 15(12):e0242953. Chow DS, Glavis-Bloom J, Soun JE, Weinberg B, Loveless TB, Xie X, Mutasa S, Monuki E, Park JI, Bota D, Wu J, Thompson L, Boden-Albala B, Khan S, Amin AN, Chang PD. PMID: 33296357.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer's disease. Nat Commun. 2020 10 23; 11(1):5370. McQuade A, Kang YJ, Hasselmann J, Jairaman A, Sotelo A, Coburn M, Shabestari SK, Chadarevian JP, Fote G, Tu CH, Danhash E, Silva J, Martinez E, Cotman C, Prieto GA, Thompson LM, Steffan JS, Smith I, Davtyan H, Cahalan M, Cho H, Blurton-Jones M. PMID: 33097708.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    4. Calcium Dynamics in Astrocytes During Cell Injury. Front Bioeng Biotechnol. 2020; 8:912. Wakida NM, Gomez-Godinez V, Li H, Nguyen J, Kim EK, Dynes JL, Othy S, Lau AL, Ding P, Shi L, Carmona C, Thompson LM, Cahalan MD, Berns MW. PMID: 32984268.
      View in: PubMed   Mentions:
    5. Aberrant Development Corrected in Adult-Onset Huntington's Disease iPSC-Derived Neuronal Cultures via WNT Signaling Modulation. Stem Cell Reports. 2020 03 10; 14(3):406-419. Smith-Geater C, Hernandez SJ, Lim RG, Adam M, Wu J, Stocksdale JT, Wassie BT, Gold MP, Wang KQ, Miramontes R, Kopan L, Orellana I, Joy S, Kemp PJ, Allen ND, Fraenkel E, Thompson LM. PMID: 32109367.
      View in: PubMed   Mentions:    Fields:    
    6. Microglial depletion prevents extracellular matrix changes and striatal volume reduction in a model of Huntington's disease. Brain. 2020 01 01; 143(1):266-288. Crapser JD, Ochaba J, Soni N, Reidling JC, Thompson LM, Green KN. PMID: 31848580.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    7. A short note for Mike. J Neurosci Res. 2019 Dec; 97(12):1748. Thompson LM. PMID: 31612586.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    8. IKKß slows Huntington's disease progression in R6/1 mice. Proc Natl Acad Sci U S A. 2019 05 28; 116(22):10952-10961. Ochaba J, Fote G, Kachemov M, Thein S, Yeung SY, Lau AL, Hernandez S, Lim RG, Casale M, Neel MJ, Monuki ES, Reidling J, Housman DE, Thompson LM, Steffan JS. PMID: 31088970.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    9. Fractionation for Resolution of Soluble and Insoluble Huntingtin Species. J Vis Exp. 2018 02 27; (132). Ochaba J, Morozko EL, O'Rourke JG, Thompson LM. PMID: 29553509.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    10. Cellular Models: HD Patient-Derived Pluripotent Stem Cells. Methods Mol Biol. 2018; 1780:41-73. Geater C, Hernandez S, Thompson L, Mattis VB. PMID: 29856014.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    11. Longitudinal Biochemical Assay Analysis of Mutant Huntingtin Exon 1 Protein in R6/2 Mice. J Huntingtons Dis. 2018; 7(4):321-335. Morozko EL, Ochaba J, Hernandez SJ, Lau A, Sanchez I, Orellana I, Kopan L, Crapser J, Duong JH, Overman J, Yeung S, Steffan JS, Reidling J, Thompson LM. PMID: 30452420.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    12. Human Neural Stem Cell Transplantation Rescues Functional Deficits in R6/2 and Q140 Huntington's Disease Mice. Stem Cell Reports. 2018 01 09; 10(1):58-72. Reidling JC, Relaño-Ginés A, Holley SM, Ochaba J, Moore C, Fury B, Lau A, Tran AH, Yeung S, Salamati D, Zhu C, Hatami A, Cepeda C, Barry JA, Kamdjou T, King A, Coleal-Bergum D, Franich NR, LaFerla FM, Steffan JS, Blurton-Jones M, Meshul CK, Bauer G, Levine MS, Chesselet MF, Thompson LM. PMID: 29233555.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    13. Huntington's Disease iPSC-Derived Brain Microvascular Endothelial Cells Reveal WNT-Mediated Angiogenic and Blood-Brain Barrier Deficits. Cell Rep. 2017 05 16; 19(7):1365-1377. Lim RG, Quan C, Reyes-Ortiz AM, Lutz SE, Kedaigle AJ, Gipson TA, Wu J, Vatine GD, Stocksdale J, Casale MS, Svendsen CN, Fraenkel E, Housman DE, Agalliu D, Thompson LM. PMID: 28514657.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    14. PIAS1 Regulates Mutant Huntingtin Accumulation and Huntington's Disease-Associated Phenotypes In Vivo. Neuron. 2016 05 04; 90(3):507-20. Ochaba J, Monteys AM, O'Rourke JG, Reidling JC, Steffan JS, Davidson BL, Thompson LM. PMID: 27146268.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    15. Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes. Neuron. 2015 Jan 21; 85(2):303-15. Lee JH, Tecedor L, Chen YH, Monteys AM, Sowada MJ, Thompson LM, Davidson BL. PMID: 25556834.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimalsCells
    16. Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington's disease. Hum Mol Genet. 2015 Mar 15; 24(6):1602-16. Liu KY, Shyu YC, Barbaro BA, Lin YT, Chern Y, Thompson LM, James Shen CK, Marsh JL. PMID: 25398943.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    17. Potential function for the Huntingtin protein as a scaffold for selective autophagy. Proc Natl Acad Sci U S A. 2014 Nov 25; 111(47):16889-94. Ochaba J, Lukacsovich T, Csikos G, Zheng S, Margulis J, Salazar L, Mao K, Lau AL, Yeung SY, Humbert S, Saudou F, Klionsky DJ, Finkbeiner S, Zeitlin SO, Marsh JL, Housman DE, Thompson LM, Steffan JS. PMID: 25385587.
      View in: PubMed   Mentions: 75     Fields:    Translation:Animals
    18. Fibroblast growth factor receptor 3 interacts with and activates TGFß-activated kinase 1 tyrosine phosphorylation and NF?B signaling in multiple myeloma and bladder cancer. PLoS One. 2014; 9(1):e86470. Salazar L, Kashiwada T, Krejci P, Meyer AN, Casale M, Hallowell M, Wilcox WR, Donoghue DJ, Thompson LM. PMID: 24466111.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    19. Targeting H3K4 trimethylation in Huntington disease. Proc Natl Acad Sci U S A. 2013 Aug 06; 110(32):E3027-36. Vashishtha M, Ng CW, Yildirim F, Gipson TA, Kratter IH, Bodai L, Song W, Lau A, Labadorf A, Vogel-Ciernia A, Troncosco J, Ross CA, Bates GP, Krainc D, Sadri-Vakili G, Finkbeiner S, Marsh JL, Housman DE, Fraenkel E, Thompson LM. PMID: 23872847.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansAnimalsCells
    20. SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation. Cell Rep. 2013 Jul 25; 4(2):362-75. O'Rourke JG, Gareau JR, Ochaba J, Song W, Raskó T, Reverter D, Lee J, Monteys AM, Pallos J, Mee L, Vashishtha M, Apostol BL, Nicholson TP, Illes K, Zhu YZ, Dasso M, Bates GP, Difiglia M, Davidson B, Wanker EE, Marsh JL, Lima CD, Steffan JS, Thompson LM. PMID: 23871671.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    21. Exogenous delivery of chaperonin subunit fragment ApiCCT1 modulates mutant Huntingtin cellular phenotypes. Proc Natl Acad Sci U S A. 2013 Feb 19; 110(8):3077-82. Sontag EM, Joachimiak LA, Tan Z, Tomlinson A, Housman DE, Glabe CG, Potkin SG, Frydman J, Thompson LM. PMID: 23365139.
      View in: PubMed   Mentions: 26     Fields:    Translation:AnimalsCells
    22. Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models. J Neurosci. 2012 Aug 08; 32(32):11109-19. Sontag EM, Lotz GP, Agrawal N, Tran A, Aron R, Yang G, Necula M, Lau A, Finkbeiner S, Glabe C, Marsh JL, Muchowski PJ, Thompson LM. PMID: 22875942.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    23. Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background. J Huntingtons Dis. 2012; 1(2):221-41. Strong MK, Southwell AL, Yonan JM, Hayden MR, Macgregor GR, Thompson LM, Steward O. PMID: 23833693.
      View in: PubMed   Mentions: 3     Fields:    Translation:Animals
    24. Detection of Mutant Huntingtin Aggregation Conformers and Modulation of SDS-Soluble Fibrillar Oligomers by Small Molecules. J Huntingtons Dis. 2012; 1(1):119-32. Sontag EM, Lotz GP, Yang G, Sontag CJ, Cummings BJ, Glabe CG, Muchowski PJ, Thompson LM. PMID: 24086178.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    25. Pcaf modulates polyglutamine pathology in a Drosophila model of Huntington's disease. Neurodegener Dis. 2012; 9(2):104-6. Bodai L, Pallos J, Thompson LM, Marsh JL. PMID: 21912091.
      View in: PubMed   Mentions: 5     Fields:    Translation:Animals
    26. Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration. J Neurosci. 2011 May 04; 31(18):6858-70. Sleiman SF, Langley BC, Basso M, Berlin J, Xia L, Payappilly JB, Kharel MK, Guo H, Marsh JL, Thompson LM, Mahishi L, Ahuja P, MacLellan WR, Geschwind DH, Coppola G, Rohr J, Ratan RR. PMID: 21543616.
      View in: PubMed   Mentions: 55     Fields:    Translation:AnimalsCells
    27. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron. 2009 Dec 24; 64(6):828-40. Gu X, Greiner ER, Mishra R, Kodali R, Osmand A, Finkbeiner S, Steffan JS, Thompson LM, Wetzel R, Yang XW. PMID: 20064390.
      View in: PubMed   Mentions: 141     Fields:    Translation:HumansAnimalsCells
    28. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol. 2009 Dec 28; 187(7):1083-99. Thompson LM, Aiken CT, Kaltenbach LS, Agrawal N, Illes K, Khoshnan A, Martinez-Vincente M, Arrasate M, O'Rourke JG, Khashwji H, Lukacsovich T, Zhu YZ, Lau AL, Massey A, Hayden MR, Zeitlin SO, Finkbeiner S, Green KN, LaFerla FM, Bates G, Huang L, Patterson PH, Lo DC, Cuervo AM, Marsh JL, Steffan JS. PMID: 20026656.
      View in: PubMed   Mentions: 140     Fields:    Translation:HumansAnimalsCells
    29. Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity. J Biol Chem. 2009 Oct 23; 284(43):29427-36. Aiken CT, Steffan JS, Guerrero CM, Khashwji H, Lukacsovich T, Simmons D, Purcell JM, Menhaji K, Zhu YZ, Green K, Laferla F, Huang L, Thompson LM, Marsh JL. PMID: 19710014.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCells
    30. A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells. Hum Mol Genet. 2009 Jun 01; 18(11):1951-61. Salazar L, Kashiwada T, Krejci P, Muchowski P, Donoghue D, Wilcox WR, Thompson LM. PMID: 19286672.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    31. Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage. PLoS One. 2008; 3(12):e3961. Krejci P, Salazar L, Kashiwada TA, Chlebova K, Salasova A, Thompson LM, Bryja V, Kozubik A, Wilcox WR. PMID: 19088846.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    32. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci. 2008 Nov 05; 28(45):11500-10. Green KN, Steffan JS, Martinez-Coria H, Sun X, Schreiber SS, Thompson LM, LaFerla FM. PMID: 18987186.
      View in: PubMed   Mentions: 112     Fields:    Translation:HumansAnimalsCells
    33. Animal models of polyglutamine diseases and therapeutic approaches. J Biol Chem. 2009 Mar 20; 284(12):7431-5. Marsh JL, Lukacsovich T, Thompson LM. PMID: 18957429.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    34. Fibroblast growth factor inhibits interferon gamma-STAT1 and interleukin 6-STAT3 signaling in chondrocytes. Cell Signal. 2009 Jan; 21(1):151-60. Krejci P, Prochazkova J, Bryja V, Jelinkova P, Pejchalova K, Kozubik A, Thompson LM, Wilcox WR. PMID: 18950705.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    35. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum Mol Genet. 2008 Dec 01; 17(23):3767-75. Pallos J, Bodai L, Lukacsovich T, Purcell JM, Steffan JS, Thompson LM, Marsh JL. PMID: 18762557.
      View in: PubMed   Mentions: 106     Fields:    Translation:HumansAnimalsCells
    36. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347. Mol Cell Neurosci. 2008 Sep; 39(1):1-7. Conforti P, Ramos C, Apostol BL, Simmons DA, Nguyen HP, Riess O, Thompson LM, Zuccato C, Cattaneo E. PMID: 18571429.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimals
    37. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. Mol Cell Neurosci. 2008 Sep; 39(1):8-20. Apostol BL, Simmons DA, Zuccato C, Illes K, Pallos J, Casale M, Conforti P, Ramos C, Roarke M, Kathuria S, Cattaneo E, Marsh JL, Thompson LM. PMID: 18602275.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansAnimalsCells
    38. Neurodegeneration: a question of balance. Nature. 2008 Apr 10; 452(7188):707-8. Thompson LM. PMID: 18401401.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    39. STAT1 and STAT3 do not participate in FGF-mediated growth arrest in chondrocytes. J Cell Sci. 2008 Feb 01; 121(Pt 3):272-81. Krejci P, Salazar L, Goodridge HS, Kashiwada TA, Schibler MJ, Jelinkova P, Thompson LM, Wilcox WR. PMID: 18198189.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    40. Genes on distal chromosome 18 determine vulnerability to excitotoxic neurodegeneration following status epilepticus, but not striatal neurodegeneration induced by quinolinic acid. Neurobiol Dis. 2008 Mar; 29(3):391-9. McLin JP, Thompson LM, Lusis AJ, Davis RC, Steward O. PMID: 17996456.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    41. Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins. J Biol Chem. 2007 Feb 02; 282(5):2929-36. Krejci P, Masri B, Salazar L, Farrington-Rock C, Prats H, Thompson LM, Wilcox WR. PMID: 17145761.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    42. Differential susceptibility to striatal neurodegeneration induced by quinolinic acid and kainate in inbred, outbred and hybrid mouse strains. Eur J Neurosci. 2006 Dec; 24(11):3134-40. McLin JP, Thompson LM, Steward O. PMID: 17156374.
      View in: PubMed   Mentions: 19     Fields:    Translation:AnimalsCells
    43. The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum Mol Genet. 2007 Jan 01; 16(1):61-77. Rockabrand E, Slepko N, Pantalone A, Nukala VN, Kazantsev A, Marsh JL, Sullivan PG, Steffan JS, Sensi SL, Thompson LM. PMID: 17135277.
      View in: PubMed   Mentions: 113     Fields:    Translation:AnimalsCells
    44. Transcription meets metabolism in neurodegeneration. Nat Med. 2006 Nov; 12(11):1239-41. Ross CA, Thompson LM. PMID: 17088887.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    45. Drosophila in the study of neurodegenerative disease. Neuron. 2006 Oct 05; 52(1):169-78. Marsh JL, Thompson LM. PMID: 17015234.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansAnimals
    46. Normal-repeat-length polyglutamine peptides accelerate aggregation nucleation and cytotoxicity of expanded polyglutamine proteins. Proc Natl Acad Sci U S A. 2006 Sep 26; 103(39):14367-72. Slepko N, Bhattacharyya AM, Jackson GR, Steffan JS, Marsh JL, Thompson LM, Wetzel R. PMID: 16980414.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    47. Biologically active molecules that reduce polyglutamine aggregation and toxicity. Hum Mol Genet. 2006 Jul 01; 15(13):2114-24. Desai UA, Pallos J, Ma AA, Stockwell BR, Thompson LM, Marsh JL, Diamond MI. PMID: 16720620.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    48. Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Hum Mol Genet. 2006 Jan 15; 15(2):273-85. Apostol BL, Illes K, Pallos J, Bodai L, Wu J, Strand A, Schweitzer ES, Olson JM, Kazantsev A, Marsh JL, Thompson LM. PMID: 16330479.
      View in: PubMed   Mentions: 58     Fields:    Translation:AnimalsCells
    49. Sustained ERK1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells. Hum Mol Genet. 2005 Jun 01; 14(11):1529-38. Nowroozi N, Raffioni S, Wang T, Apostol BL, Bradshaw RA, Thompson LM. PMID: 15843401.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    50. Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Proc Natl Acad Sci U S A. 2005 Mar 08; 102(10):3777-81. Agrawal N, Pallos J, Slepko N, Apostol BL, Bodai L, Chang LW, Chiang AS, Thompson LM, Marsh JL. PMID: 15716359.
      View in: PubMed   Mentions: 55     Fields:    Translation:Animals
    51. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci U S A. 2005 Jan 18; 102(3):892-7. Zhang X, Smith DL, Meriin AB, Engemann S, Russel DE, Roark M, Washington SL, Maxwell MM, Marsh JL, Thompson LM, Wanker EE, Young AB, Housman DE, Bates GP, Sherman MY, Kazantsev AG. PMID: 15642944.
      View in: PubMed   Mentions: 79     Fields:    Translation:AnimalsCells
    52. Can flies help humans treat neurodegenerative diseases? Bioessays. 2004 May; 26(5):485-96. Marsh JL, Thompson LM. PMID: 15112229.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    53. SUMO modification of Huntingtin and Huntington's disease pathology. Science. 2004 Apr 02; 304(5667):100-4. Steffan JS, Agrawal N, Pallos J, Rockabrand E, Trotman LC, Slepko N, Illes K, Lukacsovich T, Zhu YZ, Cattaneo E, Pandolfi PP, Thompson LM, Marsh JL. PMID: 15064418.
      View in: PubMed   Mentions: 240     Fields:    Translation:HumansAnimalsCells
    54. A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. Neuron. 2003 Nov 13; 40(4):685-94. Pollitt SK, Pallos J, Shao J, Desai UA, Ma AA, Thompson LM, Marsh JL, Diamond MI. PMID: 14622574.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansAnimalsCells
    55. Autophagy regulates the processing of amino terminal huntingtin fragments. Hum Mol Genet. 2003 Dec 15; 12(24):3231-44. Qin ZH, Wang Y, Kegel KB, Kazantsev A, Apostol BL, Thompson LM, Yoder J, Aronin N, DiFiglia M. PMID: 14570716.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansAnimalsCells
    56. An expanded role for wild-type huntingtin in neuronal transcription. Nat Genet. 2003 Sep; 35(1):13-4. Thompson LM. PMID: 12947403.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    57. Invertebrate models of neurologic disease: insights into pathogenesis and therapy. Curr Neurol Neurosci Rep. 2003 Sep; 3(5):442-8. Thompson LM, Marsh JL. PMID: 12914688.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    58. Fly models of Huntington's disease. Hum Mol Genet. 2003 Oct 15; 12 Spec No 2:R187-93. Marsh JL, Pallos J, Thompson LM. PMID: 12925571.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimals
    59. A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc Natl Acad Sci U S A. 2003 May 13; 100(10):5950-5. Apostol BL, Kazantsev A, Raffioni S, Illes K, Pallos J, Bodai L, Slepko N, Bear JE, Gertler FB, Hersch S, Housman DE, Marsh JL, Thompson LM. PMID: 12730384.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansAnimalsCells
    60. Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases. Expert Opin Ther Targets. 2003 Apr; 7(2):201-13. Steffan JS, Thompson LM. PMID: 12667098.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells